Screening for cervical cancer has dramatically helped reduce its incidence and mortality—age-adjusted death rates have been falling on average 0.7% each year over 2009–2018.1
You can count on Quest for a more complete picture to help you and your patients make more informed decisions.
Quest’s age-based Smart Codes use a patient’s age and risk factors to determine which combination of HPV and select STI screening should be performed, along with an image-guided Pap. Smart Codes are consistent with ACOG recommendationsa and are available in addition to our standard menu of tests.
Note about Smart Codes: Screening women older than 65 years who have had adequate prior screening and women younger than 21 years does not provide significant benefit. Screening women who have had a hysterectomy with removal of the cervix for indications other than a high-grade precancerous lesion or cervical cancer provides no benefit.3
With our robust cervical cancer testing menu, you can rely on Pap testing from Quest Diagnostics to help you make a more informed diagnosis and treatment plan for your patients.
While we offer a choice of Pap collection systems, Quest Diagnostics recommends the ThinPrep® Pap test, due to its proven clinical performance
|TEST CODE||TEST NAME|
Image-Guided Pap with Age-Based Screening Protocols
Image-Guided Pap with Age-Based Screening with CT/NG
Image-Guided Pap with Age-Based Screening with CT/NG, Trichomonas
The Aptima® HPV mRNA assay identifies the presence and activity of high-risk HPV infections, allowing you to identify and focus on those women who most need your care.
Leading health organizations recommend co-testing every 5 years for women ages 30 to 65 as the preferred method for cervical cancer screening, and a recent Quest Diagnostics Health Trends™ retrospective, longitudinal study confirms that co-testing with Pap and HPV together identifies more cases of cancer and precancer.2
22.5% of cancers would not have been identified with HPV alone2
Data <12 months of cancer diagnosis
11% of precancers would not have been identified with Pap alone2
Data <12 months of precancer diagnosis
Data on biopsy-confirmed cancer outcomes over the entire study period (9 years)
Co-tests prior to biopsy-confirmed cancer = 1,615
Adenocarcinoma is on the rise8
Co-tests prior to biopsy-confirmed adenocarcinoma = 479
Our co-testing solutions for cervical cancer are built on a strong combination of carefully evaluated Pap and high performing mRNA testing for high risk HPV. Ordering cervical cancer screening is efficient using one-click Smart Codes. For more information or a complete list of our tests, .